Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
about
Immunotoxicity of monoclonal antibodiesSevere Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.Crosstalk between sentinel and helper macrophages permits neutrophil migration into infected uroepithelium.The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.A Candida albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of Fungal Growth during Disseminated Infection.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRheumatoid arthritis and the complement system.Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis.Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab.Update on the use of etanercept across a spectrum of rheumatoid disorders.The changing face of spondyloarthropathies under TNF α blockade.Inflammatory arthritis: an overview for primary care physicians.Rheumatoid arthritis patients exhibit impaired Candida albicans-specific Th17 responsesCNS Demyelination with TNF-α BlockersA decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Th17 cells in immunity to Candida albicans.The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.Clinical management of septic arthritis.Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasisBeyond Candida albicans: Mechanisms of immunity to non-albicans Candida speciesSquamous carcinoma cells influence monocyte phenotype and suppress lipopolysaccharide-induced TNF-alpha in monocytesChronic Periodontitis Is Associated With Spinal Dysmobility in Patients With Ankylosing Spondylitis.Biological therapy of psoriasis.Predictors of treatment failure and mortality in native septic arthritis.Overview of β-Glucans from Laminaria spp.: Immunomodulation Properties and Applications on Biologic Models.Does infliximab increase complications after surgery for inflammatory bowel disease?Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.Effect of maternal seaweed extract supplementation on suckling piglet growth, humoral immunity, selected microflora, and immune response after an ex vivo lipopolysaccharide challenge.A life-threatening abscess in a patient treated with a tumour necrosis factor-alpha antagonist: a case report.Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab.Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.Effect of dietary seaweed extracts and fish oil supplementation in sows on performance, intestinal microflora, intestinal morphology, volatile fatty acid concentrations and immune status of weaned pigs
P2860
Q24653374-39B86987-907E-4C39-B23A-862E11DF9C49Q33157116-7BBBB145-B4DA-47EA-8346-BB6F32A73945Q34643625-ECEBFF33-E04F-425A-A6B8-B4FC70F09221Q35004526-A53B34C4-EA93-483A-946C-536D90EFA75EQ35947439-EBA6A2CD-E321-4865-9BA8-AAF79CBEBF6CQ36724093-860CF57B-2463-484C-A342-FF8E8C727A43Q36939396-1E9B821C-6507-4B53-8056-70550BE5A349Q37106755-0456AB09-D05B-4A44-ADA8-A48F06300BFCQ37146221-87AF8AFA-EA93-4674-BCC2-6FAF5477E442Q37290628-5044BE1F-7EE5-44DF-B3D6-15992C89B129Q37352654-5D789868-8DA6-471D-AA8C-B9F07100846CQ37427257-CD810D63-5B52-49D4-81C2-1F85C80C8932Q37690335-AA74F8AE-50C4-4A99-A540-F95DA48BEA24Q37719132-EB200FF0-CA5E-4A77-A765-3FE1A515A943Q37814549-58F7B5AA-4C3C-40D8-803B-AC044BF61D85Q38011298-BD2F26D9-8CE0-48CE-B5ED-179CCEC77C86Q38063474-77635A92-88E6-40B0-8C0F-08F67FBCD655Q38099554-1BD197E7-B31A-4075-86E3-A9EBD9CD2FBEQ38425063-27695627-4BC2-4ECC-80C9-381345FDBA79Q38461733-6C7602A0-0A2E-43D9-9B20-7F634D648FC5Q38567197-4C3316E3-ADC2-43F5-9D42-631043C3BE0AQ39750536-45697FD0-C486-4F6B-A6F4-5522893920A4Q40624375-0FD05BFD-BE6F-45E8-971A-16360A4AD765Q41145989-C4D31A43-04BE-4ACB-AC17-85930037328CQ41602245-16335504-91CF-48C3-90EF-6F84423DDED7Q41660949-08E79783-632A-472B-A05B-F9D6873C8043Q41876389-F4D1059B-19E9-476D-BF5A-AEEB410764ACQ42625894-C1F0766A-0200-4774-86E7-6D838C47BFF0Q42726585-9D2EA920-FE69-4E17-A45F-B917390C11CDQ43282843-62C37791-8145-4ED4-9263-57384D01825DQ43450427-3F9E1295-BF6D-4DFF-A412-1BB84217AE4EQ44168838-21F87A96-1643-457F-9560-13026A4F328CQ51286442-7E9846BE-0F48-404A-BDF3-8007B906F61BQ57122520-0EE1CFDE-0FEE-48E6-A8F5-BF3E90548741
P2860
Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@ast
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@en
type
label
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@ast
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@en
prefLabel
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@ast
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@en
P1476
Infection and musculoskeletal ...... tions during anti-TNF therapy.
@en
P2093
Anja Strangfeld
Joachim Listing
P304
P356
10.1016/J.BERH.2006.08.010
P577
2006-12-01T00:00:00Z